Is Dementia Listed as a Qualifying Condition for Medical Cannabis? 

As public awareness of medical cannabis grows, many families and care professionals are asking whether dementia qualifies for treatment under UK medical cannabis laws. While medical cannabis has been legal in the UK since 2018, its use is tightly restricted, and dementia is not currently listed as a qualifying condition under any national framework. 

To understand why, it helps to look at how medical cannabis regulation, prescribing authority, and evidence standards interact across the NHS and private sector. 

The Legal Framework for Medical Cannabis 

Medical cannabis, officially termed Cannabis-Based Medicinal Products (CBPMs), became legal to prescribe in the UK following a 2018 change to the Misuse of Drugs Regulations 2001. Under this legislation, CBPMs are classified as Schedule 2 controlled drugs, similar to morphine or methadone. 

This means that CBPMs can be prescribed only by specialist doctors listed on the General Medical Council (GMC) Specialist Register, and all handling, storage, and record-keeping must meet controlled drug standards. 

According to NHS England, cannabis prescriptions are lawful only when: 

• The product is produced by a licensed manufacturer. 

• It is prescribed for a recognised clinical indication. 

• All other licensed treatments have been considered or tried. 

• The prescriber assumes full responsibility for patient monitoring and documentation. 

Approved Indications Under NICE Guidance 

The NICE guidance on cannabis-based medicinal products (NG144) sets out the few approved uses of CBPMs in the UK. As of 2025, these are: 

• Severe treatment-resistant epilepsy (e.g., Dravet or Lennox-Gastaut syndromes). 

• Multiple sclerosis related spasticity, where standard treatment has failed. 

• Chemotherapy-induced nausea or vomiting, unresponsive to licensed antiemetics. 

Dementia does not appear on this list. NICE’s dementia guideline, NG97, specifically states that cannabinoids should not be used to manage cognitive or behavioural symptoms outside clinical research. 

This position is echoed by NHS Medicines Information (2025), which notes that while cannabis may help some patients with chronic pain or spasticity, there is no evidence supporting its use for dementia symptoms such as confusion, agitation, or memory decline. 

Why Dementia Is Not a Qualifying Condition 

Dementia is excluded from cannabis eligibility for two main reasons: limited clinical evidence and safety concerns in older adults. 

1. Insufficient Evidence 

Most research to date has involved small trials with mixed results. For instance, a 2024 review in Age and Ageing found that CBD-dominant oils were well tolerated in older adults but offered only minor benefits in sleep and anxiety (Age and Ageing, 2024). 

Similarly, a 2025 PubMed Central cohort study found that low-frequency, medically supervised cannabis use did not worsen cognition in older adults but provided no consistent therapeutic advantage for dementia (PubMed Central, 2025). 

Larger, long-term studies, such as the STAND trial at King’s College London, are still underway to explore whether THC: CBD sprays (Sativex) might help with agitation in dementia. However, this work remains in early phases and outside standard NHS practice. 

2. Safety And Ethical Oversight 

The Alzheimer’s Society warns that high-THC cannabis can cause sedation, confusion, and balance problems, particularly in frail or cognitively impaired adults. NICE and NHS England require that all CBPMs used in older adults are monitored under controlled-drug protocols, with full documentation in Medication Administration Records (MARs) and compliance with the Mental Capacity Act 2005. 

Private Clinics and Off-Label Prescribing 

While dementia is not an approved NHS indication, some private cannabis clinics in the UK operate under Home Office–approved frameworks. These clinics can legally prescribe CBPMs off-label, provided the prescribing doctor is on the GMC Specialist Register and follows all controlled-drug procedures. 

However, off-label prescribing comes with added legal and ethical responsibility. Clinicians must: 

• Document that conventional treatments were unsuitable. 

• Explain potential risks, benefits, and lack of evidence. 

• Obtain informed consent (or a best-interest decision if the patient lacks capacity). 

• Record all prescriptions and monitor data for CQC review. 

The CQC Controlled Drugs Annual Report 2024 highlights an increase in private CBPM prescribing but warns of inconsistent documentation and advises care providers to verify prescriber credentials and storage compliance. 

The Role of Multidisciplinary Oversight 

Even in research or private practice, cannabis use in dementia care must be integrated into multidisciplinary review. Teams including neurologists, geriatricians, pharmacists, and nurses evaluate the patient’s medical history, cognition, comorbidities, and potential drug interactions. 

NICE SC1, which governs medicines management in care homes, requires that all controlled drugs, including CBPMs, are recorded accurately, stored securely, and reviewed regularly. Any symptom improvement or side effects must be documented using person-centred outcomes such as mood, mobility, and alertness. 

Research And Future Direction 

Although dementia is not currently a qualifying condition, emerging research continues. The STAND trial in the UK and international studies in Canada and Israel are assessing whether balanced THC: CBD formulations may ease agitation without sedation. 

According to Alzheimer’s Research UK, early findings suggest safety at low doses, but benefits remain unproven. NICE and MHRA will require substantial new evidence before considering policy changes. 

Clinical Bottom Line 

• Dementia is not listed as a qualifying condition for medical cannabis in the UK. 

• Only three conditions currently qualify under NICE guidance (epilepsy, MS spasticity, chemotherapy nausea). 

• Any cannabis use in dementia is off-label and requires specialist prescription, legal oversight, and capacity assessment. 

• NICE and Alzheimer’s Society recommend continued reliance on behavioural and supportive therapies until more evidence emerges. 

Educational Context: AlleviMed 

AlleviMed provides educational information about UK medical cannabis eligibility and prescribing frameworks. It helps families understand how controlled-drug regulations, NICE guidance, and clinical ethics interact when cannabis is discussed for conditions like dementia. 

Takeaway 

Dementia is not recognised as a qualifying condition for medical cannabis under current UK law or NICE guidelines. While ongoing research explores possible benefits for agitation or anxiety, the evidence base remains too limited for national approval. 

For now, any use must occur under specialist supervision, within legal boundaries, and with a focus on safety, person-centred care, and evidence-based decision-making. The future of cannabis in dementia care will depend not on public demand, but on rigorous science and responsible clinical practice.